Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZM 001

Next Previous
Search
Drug Profile

ZM 001

Alternative Names: ZM-001

Latest Information Update: 19 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 28 Feb 2025 Beijing Immunochina Medical Science and Technology and Peking Union Medical College Hospital plan a phase I trial for Systemic lupus erythematosus (Treatment-experienced) in China (Parenteral, Injection) (IM19SLE01), (NCT06852573)
  • 28 Oct 2024 Beijing Immunochina Medical Science and Technology receives clinical trial approval notice from NMPA for ZM 001 in Systemic lupus erythematosus (Beijing Immunochina Medical Science and Technology website, March 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top